Biomarker ID | 740 |
PMID | 19934327 |
Year | 2009 |
Biomarker | Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.81 (0.68–0.96) |
Effect on Pathways | Pathways Include:-RORA activates circadian expression,BMAL1-CLOCK/NPAS2 activates circadian expression,Circadian rhythm,Lipid metabolism regulation by peroxisome proliferator-activated receptor alpha (PPAR-alpha),Fatty acid, triacylglycerol, and ketone body metabolism |
Experiment | Controls Vs Cancer |
Type of Biomarker | Diagnostic |
Cohort | Total of 1308 patients with Prostate cancer and 1266 patients as controls were used for this study. Out of which 873 were less agressive and 435 were more aggressive. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | PCR |
Clinical | No |
Remarks | Circadian-related genes were chosen for this study |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NPAS2 |